A novel laser-cut fully covered metal stent with anti-reflux valve in patients with malignant distal biliary obstruction refractory to conventional covered metal stent.

anti-reflux metal stent distal biliary obstruction malignant recurrent biliary obstruction refractory

Journal

Journal of hepato-biliary-pancreatic sciences
ISSN: 1868-6982
Titre abrégé: J Hepatobiliary Pancreat Sci
Pays: Japan
ID NLM: 101528587

Informations de publication

Date de publication:
Jul 2021
Historique:
revised: 08 03 2021
received: 31 01 2021
accepted: 04 04 2021
pubmed: 10 4 2021
medline: 16 10 2021
entrez: 9 4 2021
Statut: ppublish

Résumé

Stenting against recurrent biliary obstruction (RBO) after placement of covered metal stent (CMS) for distal malignant biliary obstruction (MBO) is still challenging. This study investigated the feasibility of a novel laser-cut fully CMS with anti-reflux valve in patients with distal MBO refractory to conventional CMS. Patients who underwent Duckbill-type metal stent (DMS) placement between June 2019 and May 2020 were included. Early complications, causes of RBO including non-occlusion cholangitis, and time to RBO (TRBO) were evaluated. TRBO of DMS was also compared with that of previous CMS. Thirty patients were included: pancreatic cancer/metastatic lymph nodes in 29 patients/one patient; duodenal stenosis in 13 patients. Technical and functional success were achieved in all patients. Mild cholangitis and mild pancreatitis developed in each one. Median follow-up period was 167 days (range, 23-527 days). RBO occurred in nine patients (30%): sludge formation in four patients, hemobilia in one patient, symptomatic distal stent migration in three patients, and non-occlusion cholangitis in one patient. TRBO of DMS was significantly longer than that of previous CMS (median 224 days vs median 120 days, P = .0025). DMS was successfully removed in all of six patients when re-intervention was needed. Duckbill-type metal stent might be safe and effective in patients with distal MBO refractory to conventional CMS.

Sections du résumé

BACKGROUND BACKGROUND
Stenting against recurrent biliary obstruction (RBO) after placement of covered metal stent (CMS) for distal malignant biliary obstruction (MBO) is still challenging. This study investigated the feasibility of a novel laser-cut fully CMS with anti-reflux valve in patients with distal MBO refractory to conventional CMS.
METHODS METHODS
Patients who underwent Duckbill-type metal stent (DMS) placement between June 2019 and May 2020 were included. Early complications, causes of RBO including non-occlusion cholangitis, and time to RBO (TRBO) were evaluated. TRBO of DMS was also compared with that of previous CMS.
RESULTS RESULTS
Thirty patients were included: pancreatic cancer/metastatic lymph nodes in 29 patients/one patient; duodenal stenosis in 13 patients. Technical and functional success were achieved in all patients. Mild cholangitis and mild pancreatitis developed in each one. Median follow-up period was 167 days (range, 23-527 days). RBO occurred in nine patients (30%): sludge formation in four patients, hemobilia in one patient, symptomatic distal stent migration in three patients, and non-occlusion cholangitis in one patient. TRBO of DMS was significantly longer than that of previous CMS (median 224 days vs median 120 days, P = .0025). DMS was successfully removed in all of six patients when re-intervention was needed.
CONCLUSIONS CONCLUSIONS
Duckbill-type metal stent might be safe and effective in patients with distal MBO refractory to conventional CMS.

Identifiants

pubmed: 33835728
doi: 10.1002/jhbp.966
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

563-571

Informations de copyright

© 2021 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Références

Nakai Y, Isayama H, Wang HP, Rerknimitr R, Khor C, Yasuda I, et al. International consensus statements for endoscopic management of distal biliary stricture. J Gastroenterol Hepatol. 2020;35:967-79.
Davids PH, Groen AK, Rauws EA, Tytgat GN, Huibregtse K. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet. 1992;340:1488-92.
Al ST, Halabi S, Parsi MA, Vargo JJ. Self-expandable metal stents versus plastic stents for malignant biliary obstruction: a meta-analysis. Gastrointest Endosc. 2015;82:256-267.e7.
Tringali A, Hassan C, Rota M, Rossi M, Mutignani M, Aabakken L. Covered vs. uncovered self-expandable metal stents for malignant distal biliary strictures: a systematic review and meta-analysis. Endoscopy. 2018;50:631-41.
Misra SP, Dwivedi M. Reflux of duodenal contents and cholangitis in patients undergoing self-expandable metal stent placement. Gastrointest Endosc. 2009;70:317-21.
Zhang R, Luo H, Pan Y, Zhao L, Dong J, Liu Z, et al. Rate of duodenal-biliary reflux increases in patients with recurrent common bile duct stones: evidence from barium meal examination. Gastrointest Endosc. 2015;82:660-5.
Hamada T, Isayama H, Nakai Y, Togawa O, Kogure H, Kawakubo K, et al. Duodenal invasion is a risk factor for the early dysfunction of biliary metal stents in unresectable pancreatic cancer. Gastrointest Endosc. 2011;74:548-55.
Hu B, Wang TT, Shi ZM, Wang SZ, Lu R, Pan YM, et al. A novel antireflux metal stent for the palliation of biliary malignancies: a pilot feasibility study (with video). Gastrointest Endosc. 2011;73:143-8.
Lee KJ, Chung MJ, Park JY, Lee DH, Jung S, Bang BW, et al. Clinical advantages of a metal stent with an S-shaped anti-reflux valve in malignant biliary obstruction. Dig Endosc. 2013;25:308-12.
Kim DU, Kwon CI, Kang DH, Ko KH, Hong SP. New antireflux self-expandable metal stent for malignant lower biliary obstruction: in vitro and in vivo preliminary study. Dig Endosc. 2013;25:60-6.
Hu B, Wang TT, Wu J, Shi ZM, Gao DJ, Pan YM. Antireflux stents to reduce the risk of cholangitis in patients with malignant biliary strictures: a randomized trial. Endoscopy. 2014;46:120-6.
Hamada T, Isayama H, Nakai Y, Kogure H, Togawa O, Kawakubo K, et al. Novel antireflux covered metal stent for recurrent occlusion of biliary metal stents: a pilot study. Dig Endosc. 2014;26:264-9.
Hamada T, Isayama H, Nakai Y, Togawa O, Kogure H, Takahara N, et al. Antireflux metal stent with an antimigration system for distal malignant biliary obstruction: a feasibility pilot study. Surg Laparosc Endosc Percutan Tech. 2015;25:212-7.
Lee YN, Moon JH, Choi HJ, Choi MH, Lee TH, Cha SW, et al. Effectiveness of a newly designed antireflux valve metal stent to reduce duodenobiliary reflux in patients with unresectable distal malignant biliary obstruction: a randomized, controlled pilot study (with videos). Gastrointest Endosc. 2016;83:404-12.
Hamada T, Isayama H, Nakai Y, Togawa O, Takahara N, Uchino R, et al. Antireflux metal stent as a first-line metal stent for distal malignant biliary obstruction: a pilot study. Gut Liv. 2017;11:142-8.
Morita S, Arai Y, Sugawara S, Sone M, Sakamoto Y, Okusaka T, et al. Antireflux metal stent for initial treatment of malignant distal biliary obstruction. Gastroenterol Res Pract. 2018;2018:3805173.
Hamada T, Isayama H, Nakai Y, Iwashita T, Ito Y, Mukai T, et al. Antireflux covered metal stent for nonresectable distal malignant biliary obstruction: multicenter randomized controlled trial. Dig Endosc. 2019;31:566-74.
Kin T, Ishii K, Okabe Y, Itoi T, Katanuma A. Feasibility of biliary stenting to distal malignant biliary obstruction using a novel designed metal stent with duckbill-shaped anti-reflux valve. Dig Endosc 2020 Sep 2. https://doi.org/10.1111/den.13827. Online ahead of print.
Togawa O, Isayama H, Tsujino T, Nakai Y, Kogure H, Hamada T, et al. Management of dysfunctional covered self-expandable metallic stents in patients with malignant distal biliary obstruction. J Gastroenterol. 2013;48:1300-7.
Mutignani M, Tringali A, Shah G, Perri V, Familiari P, Iacopini F, et al. Combined endoscopic stent insertion in malignant biliary and duodenal obstruction. Endoscopy. 2007;39:440-7.
Isayama H, Hamada T, Yasuda I, Itoi T, Ryozawa S, Nakai Y, et al. Tokyo criteria 2014 for transpapillary biliary stenting. Dig Endosc. 2015;27:259-64.
Hamada T, Nakai Y, Isayama H. TOKYO criteria: standardized reporting system for endoscopic biliary stent placement. Gastrointest Interv. 2018;7:46-51.
Cotton PB, Eisen GM, Aabakken L, Baron TH, Hutter MM, Jacobson BC, et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010;71:446-54.
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452-8.
Renno A, Abdel-Aziz Y, Ahmed T, Alastal Y, Toseef J, Al-Abboodi Y, et al. Antireflux valve metal stent versus conventional self-expandable metal stent in distal malignant biliary obstruction: a systematic review and meta-analysis. Ann Gastroenterol. 2019;32:605-13.
Mandai K, Nakamura S, Uno K, Yasuda K. Successful re-intervention through stent mesh after novel antireflux covered metal biliary stent placement. Endoscopy. 2021;53(03):E94-E95. https://doi.org/10.1055/a-1201-3045
Kwon CI, Moon JP, Yun H, Jeong S, Koh DH, Lee WJ, et al. Evaluation of valve function in antireflux biliary metal stents. BMC Gastroenterol. 2018;18:150.
Nakai Y, Isayama H, Kogure H, Hamada T, Togawa O, Ito Y, et al. Risk factors for covered metallic stent migration in patients with distal malignant biliary obstruction due to pancreatic cancer. J Gastroenterol Hepatol. 2014;29:1744-9.
Sohal DPS, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, et al. Mestatatic pancreatic cancer: ASCO guideline update. J Clin Oncol. 2020 Aug 5:JCO2001364. https://doi.org/10.1200/JCO.20.01364. Online ahead of print.
Sasaki T, Takeda T, Sasahira N. Double stenting with EUS-CDS using a new anti-reflux metal stent for combined malignant biliary and duodenal obstruction. J Hepatobiliary Pancreat Sci. 2020;27:e15-e16.

Auteurs

Yuto Yamada (Y)

Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Omori Medical Center, Toho University, Tokyo, Japan.

Takashi Sasaki (T)

Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

Tsuyoshi Takeda (T)

Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

Takafumi Mie (T)

Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

Takaaki Furukawa (T)

Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

Akiyoshi Kasuga (A)

Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

Masato Matsuyama (M)

Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

Masato Ozaka (M)

Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

Yoshinori Igarashi (Y)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Omori Medical Center, Toho University, Tokyo, Japan.

Naoki Sasahira (N)

Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH